Aerosolized beta2-agonists do not induce bronchial hyperreactivity in healthy adults

Objective:To determine whether regular administration of beta2 agonists could induce bronchial hyperreactivity in nonasthmatic volunteers.Design:A prospective, randomized, double-blind, placebo-controlled, crossover clinical trial of 2 weeks therapy with a 2-week washout period between each treatment period. Treatments were albuterol or matching placebo as 2 inhalations 4 times daily.Subjects:Ten healthy, nonsmoking women 27—37 years old.Setting:General clinical research center of a tertiary care university hospital.Main Outcome Measures:Baseline spirometry and methacholine bronchoprovocation studies were performed immediately prior to, 12 hours following, and 1 and 2 weeks following each treatment period.Results:No change was detected in either baseline spirometry or methacholine responsiveness.Conclusions:This suggests that if beta2-agonists induce a rebound bronchial hyperreactivity, it is not the result of the production of tolerance or a direct effect on bronchial smooth muscle.